THE US Food and Drug
Administration has granted
approval for Tresiba (insulin
degludec injection) and Ryzodeg
70/30 (insulin degludec/insulin
aspart injection) to improve glucose
control in adults with diabetes.
Tresiba is a long-acting once daily
insulin analog injection designed to
improve glycaemic control in adults
with type 1 and type 2 diabetes,
with dosing individualised based on
the patients’ needs.
Ryzodeg 70/30 is administered
once or twice daily in combination
with mealtime insulin.
Both medications are made by
Novo Nordisk.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Sep 15
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.